Psychiatric Bulletin (2000) 24: 130-132. doi: 10.1192/pb.24.4.130
© 2000 The Royal College of Psychiatrists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Yorston, G.
Right arrow Articles by Pinney, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Yorston, G.
Right arrow Articles by Pinney, A.
Psychiatric Bulletin (2000) 24: 130-132
© 2000 The Royal College of Psychiatrists

Chlorpromazine equivalents and percentage of British National Formulary maximum recommended dose in patients receiving high-dose antipsychotics

Graeme Yorston, Consultant in Old Age Psychiatry and Alison Pinney, Clinical Pharmacist

Udston Hospital, Farm Road, Hamilton ML3 9LA

AIMS AND METHOD

The study compared two methods of identifying patients prescribed high doses of antipsychotic medication among in-patients and out-patients in Buckinghamshire. High doses were defined as those in excess of 1000 mg chlorpromazine equivalents (CPZE) per day or more than 100% of the maximum recommended dose in the British National Formulary (BNF).

RESULTS

A total of 258 patients were identified as being prescribed antipsychotics, 30 of whom received high doses. There was 93% concordance between the two methods for identifying these patients. Nine of the 12 patients who had been prescribed high potency (> 1000 mg CPZE/day) but low toxicity (> 100% BNF maximum) therapy were receiving flupenthixol decanoate.

A group of six high-risk patients were identified who had been prescribed lower potency drugs at supra-maximal doses.

CLINICAL IMPLICATIONS

Expressing total antipsychotic dose as a percentage of the BNF maximum is easy to understand and calculate. It helps to ensure patients at risk of antipsychotic toxicity are easily identified to ensure monitoring guidelines can be followed.




This article has been cited by other articles:


Home page
 Br. J. PsychiatryHome page
A. Connolly and D. Taylor
Ethnicity and quality of antipsychotic prescribing among in-patients in south London
The British Journal of Psychiatry, August 1, 2008; 193(2): 161 - 162.
[Abstract] [Full Text] [PDF]

Home page
 Psychiatr. Bull.Home page
G. B. K. Hung and H. K. Cheung
A survey of in-patient and out-patient antipsychotic prescriptions in Hong Kong
Psychiatr. Bull., March 1, 2008; 32(3): 103 - 105.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
A. Connolly, P. Rogers, and D. Taylor
Antipsychotic prescribing quality and ethnicity -- a study of hospitalized patients in south east London
J Psychopharmacol, March 1, 2007; 21(2): 191 - 197.
[Abstract] [PDF]

Home page
 Psychiatr. Bull.Home page
C. Haw and J. Stubbs
Combined antipsychotics for 'difficult-to-manage' and forensic patients with schizophrenia: reasons for prescribing and perceived benefits
Psychiatr. Bull., December 1, 2003; 27(12): 449 - 452.
[Abstract] [Full Text] [PDF]

Home page
 Psychiatr. Bull.Home page
F. Hynes
Real-life prescribing
Psychiatr. Bull., October 1, 2003; 27(10): 394 - 394.
[Full Text] [PDF]

Home page
 Psychiatr. Bull.Home page
M. Harrington, P. Lelliott, C. Paton, C. Okocha, R. Duffett, and T. Sensky
The results of a multi-centre audit of the prescribing of antipsychotic drugs for in-patients in the UK
Psychiatr. Bull., November 1, 2002; 26(11): 414 - 418.
[Abstract] [Full Text] [PDF]